» Articles » PMID: 24448468

LZTS1 Downregulation Confers Paclitaxel Resistance and is Associated with Worse Prognosis in Breast Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Jan 23
PMID 24448468
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The Leucine Zipper Tumor Suppressor 1 (LZTS1) is a tumor suppressor gene, located at chromosome 8p22, which is frequently altered in human cancer. In normal tissue, its ubiquitous expression regulates cell mitosis by the stabilization of microtubule networks. LZTS1-deficient mouse embryonic fibroblasts have been shown to have an accelerated mitotic progression, and a higher resistance to taxanes, microtubule-stabilizing drugs. We investigate the role of Lzts1 in paclitaxel-resistance in breast cancer cells. Downregulation of Lzts1 expression significantly decreases sensitivity to paclitaxel in vitro. We further analyzed Lzts1 expression by immunohistochemistry in 270 primary breast cancer samples and 16 normal breast specimens. Lzts1 was significantly downregulated in breast cancer samples and its deregulation was associated with a higher incidence of tumor recurrence, and to a worse overall survival. Moreover, Lzts1-negative tumors were associated with unfavorable outcome after taxanes-based therapy. Thus our data suggest that Lzts1 deregulation is involved in breast cancer and its immunohistochemical evaluation may serve as a prognostic factor for breast cancer therapy.

Citing Articles

Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B Breast Cancer: A Pilot Study.

Camargo-Herrera V, Castellanos G, Rangel N, Jimenez-Tobon G, Martinez-Aguero M, Rondon-Lagos M Int J Mol Sci. 2024; 25(8).

PMID: 38674062 PMC: 11049937. DOI: 10.3390/ijms25084478.


Reduced sister chromatid cohesion acts as a tumor penetrance modifier.

Wang J, Thomas H, Chen Y, Percival S, Waldrep S, Ramaker R PLoS Genet. 2022; 18(8):e1010341.

PMID: 35994499 PMC: 9436123. DOI: 10.1371/journal.pgen.1010341.


Application of an open-chamber multi-channel microfluidic device to test chemotherapy drugs.

Moon H, Yoo C, Kim S, Lee J, Park W Sci Rep. 2020; 10(1):20343.

PMID: 33230163 PMC: 7683738. DOI: 10.1038/s41598-020-77324-3.


Mechanisms of Taxane Resistance.

Maloney S, Hoover C, Morejon-Lasso L, Prosperi J Cancers (Basel). 2020; 12(11).

PMID: 33182737 PMC: 7697134. DOI: 10.3390/cancers12113323.


Altered mitochondrial trafficking as a novel mechanism of cancer metastasis.

Furnish M, Caino M Cancer Rep (Hoboken). 2020; 3(1):e1157.

PMID: 32671955 PMC: 7370516. DOI: 10.1002/cnr2.1157.


References
1.
Toyooka S, Fukuyama Y, Wistuba I, Tockman M, Minna J, Gazdar A . Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res. 2002; 8(7):2292-7. View

2.
Sepulveda J, Lebovitz R, Thompson T, Chinault A . Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene. 2001; 20(31):4169-79. DOI: 10.1038/sj.onc.1204539. View

3.
. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

4.
Schiff P, Horwitz S . Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry. 1981; 20(11):3247-52. DOI: 10.1021/bi00514a041. View

5.
Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H . FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol. 2002; 160(4):1345-52. PMC: 1867220. DOI: 10.1016/S0002-9440(10)62561-8. View